Search results for "Infectious uveitis"

showing 5 items of 5 documents

New insights into the genetic component of non-infectious uveitis through an Immunochip strategy.

2016

BACKGROUND: Large-scale genetic studies have reported several loci associated with specific disorders involving uveitis. Our aim was to identify genetic risk factors that might predispose to uveitis per se, independent of the clinical diagnosis, by performing a dense genotyping of immune-related loci.METHODS: 613 cases and 3693 unaffected controls from three European case/control sets were genotyped using the Immunochip array. Only patients with non-infectious non-anterior uveitis and without systemic features were selected. To perform a more comprehensive analysis of the human leucocyte antigen (HLA) region, SNPs, classical alleles and polymorphic amino acid variants were obtained via impu…

0301 basic medicineMale*meta-analysisSingle-nucleotide polymorphismHuman leukocyte antigenBiology*human leukocyte antigenPolymorphism Single NucleotideWhite PeopleUveitis03 medical and health sciences0302 clinical medicine*Immunochiphuman leukocyte antigenHLA AntigensRisk FactorsGeneticsmedicineJournal ArticleHumansGenotypingGenetics (clinical)Allelesnon-anterior uveitisGeneticsHaplotypenon-infectious uveitisImmunochipMiddle Agedmedicine.diseaseBirdshot chorioretinopathymeta-analysis030104 developmental biologyHaplotypesGenetic Loci*non-anterior uveitisCase-Control StudiesImmunology*non-infectious uveitis030221 ophthalmology & optometryIntermediate uveitisFemaleGene polymorphismUveitis
researchProduct

Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study

2021

The purpose of this study was to identify circulating biomarkers of recurrent non-infectious anterior uveitis (NIAU), and to address the anti-inflammatory effects of triglyceride containing docosahexaenoic acid (DHA-TG). A prospective multicenter study was conducted in 72 participants distributed into: patients diagnosed with recurrent NIAU in the quiescence stage (uveitis group (UG)

0301 basic medicineMedicine (General)medicine.medical_specialtyClinical BiochemistryÀcids grassos omega-3GastroenterologyArticlerecurrent anterior non-infectious uveitisUveitis03 medical and health scienceschemistry.chemical_compoundR5-9200302 clinical medicineOral administrationInternal medicineOmega-3 fatty acidsMedicineTriglicèridsStage (cooking)Triglyceridesomega-3 fatty acidsTriglyceridebusiness.industryInterleukintriglyceride of docosahexaenoic acidmedicine.diseasecytokinesCirculating biomarkers030104 developmental biologychemistryDocosahexaenoic acidUveïtis030221 ophthalmology & optometryTumor necrosis factor alphabusinessUveitisDiagnostics
researchProduct

Noninfectious uveitis: strategies to optimize treatment compliance and adherence.

2015

Noninfectious uveitis includes a heterogenous group of sight-threatening ocular and systemic disorders. Significant progress has been made in the treatment of noninfectious uveitis in recent years, particularly with regard to the effective use of corticosteroids and non-corticosteroid immunosuppressive drugs, including biologic agents. All of these therapeutic approaches are limited, however, by any given patient's ability to comply with and adhere to their prescribed treatment. In fact, compliance and adherence are among the most important patient-related determinants of treatment success. We discuss strategies to optimize compliance and adherence.

Immunosuppressive treatmentmedicine.medical_specialtynoninfectious uveitisbusiness.industryintraocular inflammationimmunosuppressive treatmentReviewcomplianceBiologic AgentsIntraocular inflammationOphthalmologyInfectious uveitisTreatment successTreatment complianceOphthalmologymedicinetherapeutic failureTherapeutic failureadherenceIntensive care medicinebusinessClinical ophthalmology (Auckland, N.Z.)
researchProduct

Non-infectious uveitis burden on quality of life and work impairment assessed through different psychometric questionnaires

2021

Background: The purpose of this study was to evaluate the association between a novel psychometric 12-item questionnaire (U-qest) and other validated questionnaires to assess quality of life and work impairment in patients with non-infectious uveitis. Methods: Data were collected at baseline and 3 months postbaseline using U-qest and two other validated questionnaires: The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and the 12-Item Short-Form Health Survey (SF-12). Results: A total of 136 patients (52.2% female) aged 47.9 ± 14.8 years (mean ± SD) were enrolled in 14 uveitis referral centres. U-qest correlated moderately with VFQ-25 and SF-12 at baseline and at 3 mo…

Malemedicine.medical_specialtyQoLPsychometricsReferralVisual Acuityuveitis questionnaire; QoL; disease burden; work impairmentDiseaseAffect (psychology)Uveitisdisease burdenInfectious uveitisQuality of lifeCronbach's alphawork impairmentSurveys and QuestionnairesmedicineHumansDisease burdenbusiness.industryReproducibility of ResultsGeneral Medicinemedicine.diseaseOphthalmologyQoL; Uveitis questionnaire; disease burden; work impairmentQuality of LifePhysical therapydisease burden QoL Uveitis questionnaire work impairmentFemalebusinessUveitis questionnaireUveitisuveitis questionnaire
researchProduct

Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.

2012

Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrol…

medicine.medical_specialtyTreatment protocolCyclophosphamideAdministration TopicalImmunologyAnti-Inflammatory AgentsAzathioprineUveitisInfectious uveitisAdrenal Cortex HormonesmedicineImmunology and AllergyAnimalsHumansIntensive care medicinePharmacologyChlorambucilbusiness.industryTumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseTacrolimusSurgeryInjections IntravenousPractice Guidelines as TopicMethotrexateImmunotherapybusinessUveitisAlgorithmsImmunosuppressive Agentsmedicine.drugInflammationallergy drug targets
researchProduct